|
Cadmium poisoning
|
0.200 |
Biomarker
|
disease |
RGD |
Intracellular distribution of the antimutagenic enzyme MTH1 in the liver, kidney and testis of F344 rats and its modulation by cadmium.
|
11817101 |
2001 |
|
Injury of liver
|
0.200 |
Biomarker
|
disease |
RGD |
Immunohistochemical detection of 8-hydroxy-2'-deoxyguanosine in paraffin-embedded sections of rat liver after carbon tetrachloride treatment.
|
9547863 |
1998 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
HIF-1α protein expression was correlated significantly with MTH-1 expression (R = 0.640; P < 0.01) in human CRC tissues.
|
26730155 |
2015 |
|
Colorectal Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Heterozygous variants of rs1799832 in NUDT1 (HR = 2.97, 95% CI = 1.51-5.83) and rs13181 in ERCC2 (HR = 2.69, 95% CI = 1.10-6.55) were significantly associated with an increased risk of CRC compared with wild-type homozygous CC and TT genotypes, respectively.
|
29664240 |
2018 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
MTH1 mRNA was also higher in CRC patients.
|
20534734 |
2010 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
We have used the chimeric ATP-releasing guanine-oxidized (ARGO) probe that combines 8-oxodGTP and ATP to measure MTH1 enzymatic activity in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) along with patient-matched normal tissue.
|
31311767 |
2019 |
|
Colorectal Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Mutations in MUTYH have been associated with increased colorectal cancer (CRC) risk while no association has been described for OGG1 or NUDT1.
|
21355073 |
2011 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Genetic investigation of DNA repair genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1, as possible susceptibility factors for sporadic CRC, was done using both a haplotype tagging and a candidate (i.e. coding) single nucleotide polymorphism (SNP) approach.
|
17417778 |
2007 |
|
Colorectal Carcinoma
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the contribution of NUDT1 and OGG1 germline mutations to hereditary CRC and to polyposis is inexistent or, at most, negligible.
|
29900613 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We have used the chimeric ATP-releasing guanine-oxidized (ARGO) probe that combines 8-oxodGTP and ATP to measure MTH1 enzymatic activity in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) along with patient-matched normal tissue.
|
31311767 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a novel antitumor mechanism of (S)-crizotinib in NSCLC which involves activation of ROS-dependent ER stress apoptotic pathway and is independent of MTH1 inhibition.
|
28882182 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Previous studies indicated that MTH1 is associated with tumor proliferation and invasion in non-small cell lung cancer (NSCLC) cell lines; however, the role of MTH1 in patients with NSCLC remains unclear.
|
28577950 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
AlteredExpression
|
disease |
LHGDN |
Expression of human MutT homologue (hMTH1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue.
|
12757855 |
2003 |
|
Non-Small Cell Lung Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Despite this, overall our cell viability data indicates that targeting MTH1 will likely not be an across-the-board effective NSCLC therapeutic strategy; rather it induces non-cytotoxic DNA damage that could promote cancer heterogeneity and evolution.
|
29661172 |
2018 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In addition, the mRNA level of MTH1 was upregulated in the liver tissues of HCC rats (<i>P</i> < 0.05 versus control group), which was reversed by HS-1200 treatment in a dose-dependent manner (<i>P</i> < 0.05 versus HCC group).<i>Conclusions</i>.
|
28261604 |
2017 |
|
Liver carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Nineteen tagging SNPs in base excision repair genes (including MUTYH, OGG1 and MTH1) were genotyped using iPLEX assays; one significant SNP was found and confirmed in Japanese patients with chronic hepatitis C (CHC) (n = 38 HCC and 55 controls).
|
30218772 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The MTH1 inhibitor Karonudib (TH1579) and siRNA effectively introduce toxic oxidized nucleotides into DNA, 8-oxoG, and kill HCC cell lines <i>in vitro</i>.
|
31489034 |
2019 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDT1, MCM7, and NUDT1 were shown to be up-regulated in HCC tissues through quantitative real-time PCR.
|
29442275 |
2018 |
|
Squamous cell carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Synergistic therapy of chemotherapeutic drugs and MTH1 inhibitors using a pH-sensitive polymeric delivery system for oral squamous cell carcinoma.
|
28744533 |
2017 |
|
Squamous cell carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression level of NUDT1 might be used to predict the prognosis of OSCC patients.
|
31732994 |
2020 |
|
Squamous cell carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The study reports the successful loading and delivery of MTH1 inhibitor - TH287 and MDR1 siRNA in oral squamous cell carcinoma.
|
30352381 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, no apparent differences in MTH1 expression were observed between distinct molecular subtypes of breast cancer.
|
28454376 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Human MutT homolog 1 (MTH1) hydrolyses oxidised nucleotide triphosphates, thereby preventing them from being incorporated into DNA; MTH1 has been found to be elevated in many types of cancers, including lung, stomach cancer, melanoma and breast cancer.
|
30569141 |
2019 |
|
Malignant tumor of colon
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Effect of MTH1 inhibition on tumour growth was explored in BRAF V600E-mutated malignant melanoma patient derived xenograft and human colon cancer SW480 and HCT116 xenograft models.
|
27827301 |
2016 |
|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
Genetic investigation of DNA-repair pathway genes PMS2, MLH1, MSH2, MSH6, MUTYH, OGG1 and MTH1 in sporadic colon cancer.
|
17417778 |
2007 |